The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It affects up to 10 per cent of women of reproductive age around the world
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Subscribe To Our Newsletter & Stay Updated
